2 years ago
SDGR
AnalystsDavid LebovitzDavid Lebovitz's Stock Forecasts
AnalystsDavid Lebovitz
Analyst Ranking
Bottom 14%
#4075 out of 4695 analysts
Average Return
-0.57%
Win Rate
47%45 out of 95
Risk vs Reward
Poor
Good
David Lebovitz's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Clementia Pharmaceuticals IncCMTA | +202.87% | $8.70 | $26.35 | 2018-08-13 - 2019-04-17 | Strong Buy |
Avexis IncAVXS | +129.75% | $94.81 | $217.83 | 2017-08-03 - 2018-05-15 | Strong Buy |
Avexis IncAVXS | +124.59% | $96.99 | $217.83 | 2017-11-13 - 2018-05-15 | Strong Buy |
Ascendis Pharma AASND | +107.40% | $71.19 | $147.65 | 2023-04-05 - 2024-04-04 | Strong Buy |
Alnylam Pharmaceuticals IncALNY | +82.31% | $147.00 | $267.99 | 2024-02-16 - 2024-10-04 | Strong Buy |
David Lebovitz Analyst Color
Get additional color on David Lebovitz's coverage of popular stocks
2 years ago
PLRX
2 years ago
ASND
David Lebovitz's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Cogent Biosciences IncCOGT | 3 | Strong Buy | $15.00 | +35.01% | Maintains | 12 days ago |
Ascendis Pharma AASND | 11 | Strong Buy | $207.00 | +45.09% | Maintains | 19 days ago |
Madrigal Pharmaceuticals IncMDGL | 4 | Strong Buy | $371.00 | +78.01% | Maintains | 2 months ago |
Alnylam Pharmaceuticals IncALNY | 22 | Strong Buy | $342.00 | +27.62% | Maintains | 2 months ago |
Incyte CorpINCY | 3 | Strong Buy | $88.00 | +30.39% | Maintains | 2 months ago |
Mirum Pharmaceuticals IncMIRM | 4 | Strong Buy | $64.00 | +63.02% | Maintains | 4 months ago |
Ptc Therapeutics IncPTCT | 7 | Strong Sell | $26.00 | -25.93% | Maintains | 5 months ago |
Intellia Therapeutics IncNTLA | 3 | Hold | $29.00 | +61.20% | Maintains | 5 months ago |
Pliant Therapeutics IncPLRX | 4 | Strong Buy | $44.00 | +281.61% | Maintains | 5 months ago |
Blueprint Medicines CorpBPMC | 7 | Strong Sell | $76.00 | -14.23% | Maintains | 5 months ago |
Schrodinger IncSDGR | 7 | Strong Buy | $37.00 | +111.31% | Maintains | 5 months ago |
Biomarin Pharmaceutical IncBMRN | 4 | Hold | $91.00 | +30.92% | Maintains | 5 months ago |
Crinetics Pharmaceuticals IncCRNX | 1 | Strong Buy | $68.00 | +27.96% | Initiates Coverage On | 7 months ago |
Bridgebio Pharma IncBBIO | 2 | Strong Buy | $46.00 | +82.32% | Maintains | 7 months ago |
Exelixis IncEXEL | 1 | Strong Buy | $31.00 | +16.28% | Initiates Coverage On | 10 months ago |
Ionis Pharmaceuticals IncIONS | 9 | Strong Buy | $60.00 | N/A | Upgrades | a year ago |
Immuneering CorpIMRX | 2 | Hold | $12.00 | N/A | Maintains | 2 years ago |
Arcutis Biotherapeutics IncARQT | 5 | Strong Buy | $36.00 | N/A | Maintains | 2 years ago |
Syndax Pharmaceuticals IncSNDX | 1 | Hold | $21.00 | N/A | Maintains | 3 years ago |
Karyopharm Therapeutics IncKPTI | 2 | Strong Buy | $27.00 | N/A | Maintains | 3 years ago |
Ironwood Pharmaceuticals IncIRWD | 5 | Hold | $14.00 | N/A | Maintains | 3 years ago |
Tectonic Therapeutic IncTECX | 7 | Strong Buy | $300.00 | N/A | Maintains | 3 years ago |
Epizyme IncEPZM | 2 | Strong Sell | $5.00 | N/A | Downgrades | 3 years ago |
Rhythm Pharmaceuticals IncRYTM | 2 | Strong Buy | $57.00 | N/A | Maintains | 4 years ago |
Macrogenics IncMGNX | 1 | Strong Sell | $15.00 | N/A | Maintains | 4 years ago |
Gw Pharmaceuticals PLCGWPH | 1 | Hold | $220.00 | N/A | Downgrades | 4 years ago |
Nabriva Therapeutics PLCNBRVF | 2 | Hold | $500.00 | N/A | Maintains | 4 years ago |
Zealand Pharma AZEAL | 1 | Strong Buy | $37.00 | N/A | Maintains | 4 years ago |
Clementia Pharmaceuticals IncCMTA | 2 | Strong Buy | $26.00 | N/A | Maintains | 6 years ago |
Avexis IncAVXS | 3 | Strong Buy | $129.00 | N/A | Maintains | 7 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.